Modus Advisors LLC Purchases 640 Shares of Eli Lilly and Company $LLY

Modus Advisors LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 48.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,952 shares of the company’s stock after purchasing an additional 640 shares during the period. Modus Advisors LLC’s holdings in Eli Lilly and Company were worth $1,489,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of LLY. Lazard Freres Gestion S.A.S. grew its holdings in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Exencial Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after purchasing an additional 11,396 shares during the last quarter. Rede Wealth LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at approximately $487,000. Central Pacific Bank Trust Division grew its stake in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares during the last quarter. Finally, Oak Family Advisors LLC bought a new stake in shares of Eli Lilly and Company during the third quarter worth $1,979,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday. Leerink Partners set a $1,234.00 target price on Eli Lilly and Company in a report on Monday, January 5th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Loop Capital set a $950.00 price target on Eli Lilly and Company in a report on Monday, November 10th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,201.17.

Eli Lilly and Company Stock Down 7.8%

Shares of NYSE:LLY opened at $1,020.39 on Friday. The firm has a market cap of $964.66 billion, a P/E ratio of 44.46, a P/E/G ratio of 0.82 and a beta of 0.39. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The business has a fifty day simple moving average of $1,052.61 and a 200 day simple moving average of $896.17. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q4 beat and bullish 2026 guidance — Lilly reported a large revenue and EPS beat driven by Zepbound and Mounjaro, and issued FY2026 revenue and EPS guidance well above Street estimates, which triggered the initial rally. Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
• Positive Sentiment: Analysts raising targets and reaffirming conviction — Multiple firms have bumped price targets and kept overweight/buy ratings after the results, reflecting confidence in GLP-1 demand and Lilly’s runway. JPMorgan price-target raise / coverage summary
• Positive Sentiment: Capacity expansion to support volume growth — Lilly announced a large manufacturing investment (>$3.5B) to boost production capacity, supporting the company’s “volume defense” against U.S. pricing pressure. Lilly to invest over $3.5B in new manufacturing facility
• Neutral Sentiment: Sector context: GLP-1 headlines lift some peers — Pfizer’s positive GLP-1 data and broader industry activity are expanding the market opportunity (good long-term signal) but also increasing near-term competition. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Neutral Sentiment: Growing divergence with Novo — Coverage notes that Lilly’s execution and capacity have shifted investor expectations relative to Novo Nordisk, which helps explain the recent re-rating. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Negative Sentiment: Low-cost oral GLP-1 competition from Hims & Hers — News that Hims will offer a compounded oral semaglutide at ~$49/month undercut pricing expectations for branded oral therapies and prompted the post-rally selloff. This raises concerns about price resilience for upcoming oral launches (e.g., orforglipron). Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Legal/investor probes — Two investor-alerts/firm investigations (Scott+Scott and Kahn Swick & Foti) were announced regarding management decisions and the proposed Ventyx transaction, adding governance/legal noise that can weigh on sentiment. Scott+Scott investor alert Ventyx / KSF investor alert

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.